title: [Targeting ErbB receptors in breast cancer].
abstract: Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal antibody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and has been considered as bringing a "therapeutic revolution" in breast oncology. Other antibodies, directed against ErbB2 or EGFR, are being evaluated, especially lapatinib, which should be marketed in the next future. Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches.
authors.affiliation: Centre Georges-François Leclerc, rue du Professeur Marion, 21079 Dijon. pfumoleau@dijon.fnclcc.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
authors.forename: Mario
authors.initials: M
authors.lastname: Campone
authors.forename: Bruno
authors.initials: B
authors.lastname: Coudert
authors.forename: Françoise
authors.initials: F
authors.lastname: Mayer
authors.forename: Laure
authors.initials: L
authors.lastname: Favier
authors.forename: Emanuelle
authors.initials: E
authors.lastname: Ferrant
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D000077341:Lapatinib; D011799:Quinazolines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D000077341:Lapatinib; D011799:Quinazolines; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C485206:pertuzumab